[Molecular target therapy for colonic neoplasms].
Oki
Eiji
E
Ota
Mitsuhiko
M
Honbo
Takuya
T
Egashira
Akinori
A
Tokunaga
Eriko
E
Sadanaga
Noriaki
N
Morita
Masaru
M
Kakeji
Yoshihiro
Y
Maehara
Yoshihiko
Y
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D015195:Drug Design; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D066246:ErbB Receptors; D000068818:Cetuximab